Suppliers in Storm Lake, IA
8 Medicare Suppliers found. Showing 1 - 8
 Rotech Durable Medical Equipment & Medical Supplies Location: 321 W Milwaukee Ave, Storm Lake, Iowa 50588 Phone: (712) 732-9978 |
Wal-mart Pharmacy 10-1526 Durable Medical Equipment & Medical Supplies Location: 1831 Lake Ave, Storm Lake, Iowa 50588 Phone: (712) 732-7960 |
Hy Vee Pharmacy 1634 Durable Medical Equipment & Medical Supplies Location: 1250 Lake Ave, Storm Lake, Iowa 50588 Phone: (712) 732-1364 |
Hy-vee Bedels Pharmacy Durable Medical Equipment & Medical Supplies Location: 409 W 5th St, Storm Lake, Iowa 50588 Phone: (712) 732-4819 |
Walgreens #11330 Durable Medical Equipment & Medical Supplies Location: 800 Lake Ave, Storm Lake, Iowa 50588 Phone: (712) 732-0005 |
Bvrmc Pharmacy Durable Medical Equipment & Medical Supplies Location: 620 Northwestern Dr, Storm Lake, Iowa 50588 Phone: (712) 213-8065 |
Madison County Medical Equipment Durable Medical Equipment & Medical Supplies Location: 1624 Lake Ave, Storm Lake, Iowa 50588 Phone: (877) 262-7005 |
Vision Care Associates P.c. Medicare Supplier Location: 600 Ontario Street, Storm Lake, Iowa 50588 Phone: (712) 732-3233 |
News Archive
Nottingham researchers develop new 'score' to detect heart disease in younger people
Experts at The University of Nottingham have developed a new 'score' to help GPs detect heart disease in younger people - before it damages their health.
Researchers reveal potential new drug target for dementia
Researchers at King's College London have discovered how a molecular 'scaffold' which allows key parts of cells to interact, comes apart in dementia and motor neuron disease, revealing a potential new target for drug discovery.
Haemonetics net revenue increases 8% to $235.8 million in Q2 fiscal 2014
Haemonetics Corporation today reported second quarter fiscal 2014 net revenue of $235.8 million, up 8%, GAAP net income of $16.5 million and earnings per share of $0.32. Adjusted net income, exclusive of transformation, integration and deal amortization expenses detailed below, was $34.4 million, up 24%, and adjusted earnings per share were $0.66, up 24%. Excluding currency impact, net revenue was up 11% in the quarter.
OptiNose to initiate novel intranasal technology Phase III trials in acute migraine
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
FDA should be given broad regulatory authority over tobacco marketing, packaging, and distribution
A combination of increased excise taxes, nationwide indoor smoking bans, and other measures would significantly lower the U.S. smoking rate, which now hovers at around 21 percent of the adult population, says a new report from the Institute of Medicine.
› Verified 3 days ago